Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclopentanes | 15 | 2015 | 26 | 3.300 |
Why?
|
| Cyclization | 28 | 2016 | 50 | 2.320 |
Why?
|
| Palladium | 6 | 2017 | 30 | 1.990 |
Why?
|
| Stereoisomerism | 27 | 2025 | 169 | 1.700 |
Why?
|
| Ketones | 7 | 2015 | 18 | 1.600 |
Why?
|
| Fluorenes | 2 | 2022 | 26 | 1.470 |
Why?
|
| Cannabinoids | 11 | 2021 | 73 | 1.220 |
Why?
|
| Alkadienes | 4 | 2013 | 6 | 1.220 |
Why?
|
| Indicators and Reagents | 7 | 2022 | 61 | 1.050 |
Why?
|
| Catalysis | 13 | 2017 | 187 | 0.960 |
Why?
|
| Acids | 2 | 2016 | 19 | 0.960 |
Why?
|
| Benzofurans | 2 | 2016 | 22 | 0.950 |
Why?
|
| Biological Products | 3 | 2022 | 91 | 0.930 |
Why?
|
| 4-Butyrolactone | 2 | 2015 | 13 | 0.920 |
Why?
|
| Receptor, Cannabinoid, CB2 | 9 | 2021 | 38 | 0.770 |
Why?
|
| Fluorine | 1 | 2022 | 17 | 0.760 |
Why?
|
| Chrysenes | 1 | 2022 | 5 | 0.730 |
Why?
|
| Molecular Structure | 14 | 2026 | 570 | 0.710 |
Why?
|
| Ethers | 5 | 2013 | 21 | 0.640 |
Why?
|
| Azetidines | 3 | 2023 | 7 | 0.560 |
Why?
|
| Receptor, Cannabinoid, CB1 | 6 | 2021 | 41 | 0.490 |
Why?
|
| Oxidation-Reduction | 7 | 2022 | 457 | 0.480 |
Why?
|
| Indoles | 2 | 2008 | 187 | 0.480 |
Why?
|
| Amines | 3 | 2015 | 41 | 0.480 |
Why?
|
| Receptors, Drug | 6 | 2003 | 61 | 0.480 |
Why?
|
| Dioxolanes | 1 | 2015 | 3 | 0.460 |
Why?
|
| Oceans and Seas | 1 | 2015 | 18 | 0.460 |
Why?
|
| Prostaglandins | 1 | 2015 | 23 | 0.460 |
Why?
|
| Methanol | 1 | 2015 | 22 | 0.450 |
Why?
|
| Alkenes | 2 | 2013 | 17 | 0.450 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 187 | 0.430 |
Why?
|
| Imines | 2 | 2013 | 9 | 0.420 |
Why?
|
| STAT3 Transcription Factor | 5 | 2023 | 102 | 0.400 |
Why?
|
| Carbon | 1 | 2014 | 128 | 0.390 |
Why?
|
| Oxides | 1 | 2013 | 100 | 0.380 |
Why?
|
| Antineoplastic Agents | 4 | 2026 | 1019 | 0.370 |
Why?
|
| Receptors, Cannabinoid | 8 | 2015 | 31 | 0.350 |
Why?
|
| Azirines | 1 | 2010 | 2 | 0.330 |
Why?
|
| Aza Compounds | 1 | 2010 | 11 | 0.320 |
Why?
|
| Molecular Conformation | 7 | 2017 | 155 | 0.320 |
Why?
|
| Organic Chemicals | 1 | 2010 | 36 | 0.320 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2010 | 13 | 0.320 |
Why?
|
| Ovarian Neoplasms | 2 | 2025 | 415 | 0.300 |
Why?
|
| Silicon Dioxide | 2 | 2005 | 39 | 0.280 |
Why?
|
| Structure-Activity Relationship | 10 | 2021 | 506 | 0.270 |
Why?
|
| Adamantane | 3 | 2015 | 10 | 0.260 |
Why?
|
| Sulfoxides | 1 | 2025 | 18 | 0.240 |
Why?
|
| Allyl Compounds | 2 | 2003 | 55 | 0.230 |
Why?
|
| Alkaloids | 1 | 2026 | 46 | 0.230 |
Why?
|
| Ligands | 5 | 2017 | 388 | 0.230 |
Why?
|
| Molecular Probes | 3 | 2015 | 23 | 0.220 |
Why?
|
| Phytoplankton | 1 | 2024 | 5 | 0.220 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2001 | 10 | 0.220 |
Why?
|
| Salicylic Acid | 1 | 2023 | 6 | 0.210 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2025 | 134 | 0.210 |
Why?
|
| Pyrroles | 2 | 2001 | 72 | 0.210 |
Why?
|
| Cyclohexanols | 4 | 1998 | 11 | 0.210 |
Why?
|
| Vinyl Compounds | 1 | 2003 | 5 | 0.200 |
Why?
|
| Diterpenes | 3 | 2002 | 97 | 0.190 |
Why?
|
| Fluorides | 1 | 2022 | 19 | 0.190 |
Why?
|
| Camphor | 1 | 2002 | 1 | 0.190 |
Why?
|
| Furans | 1 | 2003 | 40 | 0.190 |
Why?
|
| Models, Molecular | 6 | 2014 | 876 | 0.190 |
Why?
|
| Peptides, Cyclic | 1 | 2002 | 29 | 0.180 |
Why?
|
| Esters | 2 | 2012 | 25 | 0.170 |
Why?
|
| Enzymes | 1 | 2001 | 35 | 0.170 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.160 |
Why?
|
| Amides | 3 | 2020 | 71 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 432 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2021 | 536 | 0.140 |
Why?
|
| Animals | 15 | 2024 | 16992 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1723 | 0.140 |
Why?
|
| Cannabinol | 1 | 2017 | 2 | 0.130 |
Why?
|
| Spectrophotometry, Infrared | 2 | 2007 | 31 | 0.130 |
Why?
|
| Cell Line, Tumor | 5 | 2026 | 2676 | 0.130 |
Why?
|
| Deoxyglucose | 2 | 2007 | 18 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2007 | 301 | 0.120 |
Why?
|
| Thiourea | 1 | 2015 | 10 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2022 | 1003 | 0.120 |
Why?
|
| Benzoates | 1 | 2015 | 17 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 33 | 0.110 |
Why?
|
| Mice | 10 | 2022 | 6644 | 0.110 |
Why?
|
| Glioma | 1 | 2015 | 96 | 0.110 |
Why?
|
| Alcohols | 1 | 2013 | 14 | 0.100 |
Why?
|
| Alkynes | 1 | 2013 | 52 | 0.100 |
Why?
|
| Isomerism | 2 | 2003 | 64 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 140 | 0.100 |
Why?
|
| Humans | 15 | 2026 | 43102 | 0.100 |
Why?
|
| Rats | 7 | 2017 | 3735 | 0.100 |
Why?
|
| Spleen | 4 | 2002 | 204 | 0.090 |
Why?
|
| Benzopyrans | 1 | 2012 | 25 | 0.090 |
Why?
|
| Thiophenes | 1 | 2012 | 32 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 3 | 1998 | 77 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 388 | 0.080 |
Why?
|
| Prosencephalon | 4 | 2002 | 37 | 0.080 |
Why?
|
| Streptomyces | 2 | 2001 | 22 | 0.080 |
Why?
|
| Lithium Compounds | 1 | 2009 | 9 | 0.080 |
Why?
|
| Gases | 1 | 2009 | 25 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 280 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2002 | 465 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2022 | 986 | 0.070 |
Why?
|
| Protons | 1 | 2008 | 94 | 0.070 |
Why?
|
| Cyclohexylamines | 1 | 2007 | 14 | 0.070 |
Why?
|
| Crystallization | 1 | 2007 | 88 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 140 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1124 | 0.060 |
Why?
|
| Morpholines | 1 | 2006 | 72 | 0.060 |
Why?
|
| Protein Binding | 3 | 2020 | 1082 | 0.060 |
Why?
|
| Alkylation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2007 | 204 | 0.060 |
Why?
|
| Alaska | 1 | 2025 | 62 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 280 | 0.060 |
Why?
|
| Gels | 1 | 2005 | 45 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2025 | 157 | 0.060 |
Why?
|
| Protein Prenylation | 2 | 1996 | 12 | 0.060 |
Why?
|
| Synaptosomes | 3 | 2002 | 23 | 0.060 |
Why?
|
| Harmful Algal Bloom | 1 | 2024 | 4 | 0.060 |
Why?
|
| Food Chain | 1 | 2024 | 20 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1998 | 384 | 0.050 |
Why?
|
| Apoptosis | 2 | 2022 | 1568 | 0.050 |
Why?
|
| Cations | 1 | 2003 | 50 | 0.050 |
Why?
|
| Phenylcarbamates | 1 | 2002 | 2 | 0.050 |
Why?
|
| Radioligand Assay | 2 | 2015 | 65 | 0.050 |
Why?
|
| Isotope Labeling | 1 | 2003 | 26 | 0.050 |
Why?
|
| Amylose | 1 | 2002 | 5 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 38 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 1996 | 178 | 0.050 |
Why?
|
| Carbamates | 1 | 2002 | 13 | 0.050 |
Why?
|
| NADP | 1 | 2022 | 37 | 0.050 |
Why?
|
| Bromine | 1 | 2002 | 2 | 0.050 |
Why?
|
| Trees | 1 | 2002 | 22 | 0.050 |
Why?
|
| Mandelic Acids | 1 | 2002 | 1 | 0.050 |
Why?
|
| Depsipeptides | 1 | 2002 | 8 | 0.050 |
Why?
|
| Female | 6 | 2025 | 24698 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1455 | 0.050 |
Why?
|
| Cyanobacteria | 1 | 2002 | 27 | 0.050 |
Why?
|
| Lipase | 1 | 2001 | 20 | 0.040 |
Why?
|
| Peroxidases | 1 | 2001 | 16 | 0.040 |
Why?
|
| Biotransformation | 1 | 2001 | 69 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 11 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 32 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2001 | 64 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 99 | 0.040 |
Why?
|
| beta Catenin | 1 | 2021 | 78 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 127 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 368 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 290 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2001 | 199 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 374 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2022 | 2157 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 983 | 0.040 |
Why?
|
| Kinetics | 1 | 2000 | 695 | 0.040 |
Why?
|
| Zidovudine | 1 | 1998 | 32 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 861 | 0.040 |
Why?
|
| Brain | 2 | 2010 | 1472 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 532 | 0.030 |
Why?
|
| DNA | 1 | 2020 | 592 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 712 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 945 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 655 | 0.030 |
Why?
|
| Drug Design | 1 | 1998 | 186 | 0.030 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1996 | 16 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2015 | 403 | 0.030 |
Why?
|
| Virus Replication | 1 | 1998 | 318 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 64 | 0.030 |
Why?
|
| Molecular Probe Techniques | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2015 | 144 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 968 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 109 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 408 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 486 | 0.030 |
Why?
|
| HIV-1 | 1 | 1998 | 755 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 1410 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 118 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 671 | 0.020 |
Why?
|
| Solutions | 1 | 2009 | 65 | 0.020 |
Why?
|
| Dimerization | 1 | 2009 | 112 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2009 | 71 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2009 | 79 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2009 | 229 | 0.020 |
Why?
|
| Polymers | 1 | 2009 | 155 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 12222 | 0.010 |
Why?
|
| Okadaic Acid | 2 | 1996 | 16 | 0.010 |
Why?
|
| 3T3 Cells | 2 | 1996 | 64 | 0.010 |
Why?
|
| Mevalonic Acid | 2 | 1996 | 12 | 0.010 |
Why?
|
| Membranes | 1 | 2002 | 18 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 372 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 36 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1998 | 36 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1998 | 87 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 55 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 57 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1998 | 104 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 195 | 0.010 |
Why?
|
| Transferases | 1 | 1996 | 14 | 0.010 |
Why?
|
| Sterols | 1 | 1996 | 24 | 0.010 |
Why?
|
| Ubiquinone | 1 | 1996 | 23 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 114 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1998 | 279 | 0.010 |
Why?
|
| Carcinogens | 1 | 1996 | 126 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1998 | 358 | 0.010 |
Why?
|
| Male | 1 | 2015 | 23409 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1996 | 148 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 458 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1996 | 408 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1993 | 5 | 0.010 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1993 | 29 | 0.010 |
Why?
|